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Treating triple negative breast 
cancer cells with erlotinib plus a 
select antioxidant overcomes drug 
resistance by targeting cancer cell 
heterogeneity
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Rebecca L. Farr3, Julie L Boerner1, Ramzi Mohammad1,4, Greg Dyson1, Stanley R. Terlecky3 & 
Aliccia Bollig-Fischer1
Among breast cancer patients, those diagnosed with the triple-negative breast cancer (TNBC) subtype 
have the worst prog-nosis. TNBC does not express estrogen receptor-alpha, progesterone receptor, or 
the HER2 oncogene; therefore, TNBC lacks targets for molecularly-guided therapies. The concept that 
EGFR oncogene inhibitor drugs could be used as targeted treatment against TNBC has been put forth 
based on estimates that 30–60% of TNBC express high levels of EGFR. However, results from clinical 
trials testing EGFR inhibitors, alone or in combination with cytotoxic chemotherapy, did not improve 
patient outcomes. Results herein offer an explanation as to why EGFR inhibitors failed TNBC patients 
and support how combining a select antioxidant and an EGFR-specific small molecule kinase inhibitor 
(SMKI) could be an effective, novel therapeutic strategy. Treatment with CAT-SKL—a re-engineered 
protein form of the antioxidant enzyme catalase—inhibited cancer stem-like cells (CSCs), and treatment 
with the EGFR-specific SMKI erlotinib inhibited non-CSCs. Thus, combining the antioxidant CAT-SKL 
with erlotinib targeted both CSCs and bulk cancer cells in cultures of EGFR-expressing TNBC-derived 
cells. We also report evidence that the mechanism for CAT-SKL inhibition of CSCs may depend on 
antioxidant-induced downregulation of a short alternative mRNA splicing variant of the methyl-CpG 
binding domain 2 gene, isoform MBD2c.
Triple negative breast cancer (TNBC) is a molecular subtype that accounts for approximately 15–20% of inva-
sive breast cancer diagnoses in the United States and persons diagnosed with TNBC have the lowest 5-year 
survival rates among all breast cancer patients. It occurs more prevalently in pre-menopausal women and in 
African American women1,2, and obesity is a risk factor for TNBC diagnosis3,4. TNBC does not express estrogen 
receptor-alpha, progesterone receptor, or the HER2 oncogene (a member of the epidermal growth factor family 
of receptor tyrosine kinases); therefore, TNBC lacks targets for effective, molecularly-guided breast cancer ther-
apies. The EGFR oncogene is another member of the epidermal growth factor family, and the concept that EGFR 
inhibitor drugs could be used as a targeted treatment against TNBC has been put forth based on compelling 
data estimating that between 30–60% of TNBC express high levels of EGFR5,6. However, results from clinical 
trials testing EGFR-targeted inhibitors, alone or in combination with cytotoxic chemotherapy, show little or no 
improvement in patient outcomes7. Thus, it remains that chemotherapy is the only standard of care systemic 
treatment option for TNBC.
In previous studies we identified that activation of the cell-transforming HER2 oncogene causes induction 
of intracellular reactive oxygen species (ROS) and activation of redox signaling that impinges on a variety of 
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cancer cell pathways8,9. We later observed that TNBC cell cultures overexpressing the EGFR oncogene also exhibit 
aberrantly high levels of ROS. Furthermore, treatment with the antioxidant CAT-SKL in combination with an 
EGFR-targeted small molecule kinase inhibitor (SMKI) causes a marked growth inhibitory response in TNBC 
cells that are otherwise resistant to EGFR inhibitors10. CAT-SKL is a re-engineered form of the powerful antiox-
idant enzyme catalase. Previous results indicate that the recombinant enzyme transduces the cell membrane11, 
and this is believed to be mediated by a cell-penetrating peptide sequence12. CAT-SKL is distinct from other 
antioxidant treatments due to its enzymatic reduction of ROS.
In the present study we aimed to ascertain if this novel SMKI plus antioxidant combination treatment strategy 
may have broad applicability for TNBC and for other breast cancer molecular subtypes. We also aimed to better 
understand the mechanism for its anti-cancer effectiveness. We studied whether or not CAT-SKL and EGFR 
SMKI erlotinib were acting on the same cells, or if each agent was targeting a distinct population of cells, i.e., the 
subset of cancer stem-like cells (CSCs) versus the bulk population of cancer cells. The relevance of CSCs is that 
they are identified in tumors and breast cancer-derived cell cultures as tumor initiating, self-renewing cancer 
cells that also give rise to drug resistance and metastatic recurrence13. The outcomes of our study suggest that 
an antioxidant plus EGFR SMKI combined treatment strategy could be specifically developed for treatment of 
EGFR-expressing TNBC. We report evidence that the EGFR-specific SMKI erlotinib inhibits the non-CSC or 
bulk TNBC cells and that CAT-SKL inhibits viability of the CSC sub-population. Results of further investigation 
suggest that CAT-SKL-induced downregulation of the methyl-CpG binding domain 2 gene, the MBC2C isoform 
specifically, was key to CAT-SKL targeting of CSCs.
Results
Effect of combination CAT-SKL plus EGFR-specific or HER2-specific SMKI on breast cancer cell 
line viability. We began our study by testing the effect of the combination treatment, CAT-SKL plus EGFR 
SMKI or HER2 SMKI, on cell viability across a panel of 8 cell lines. This included six EGFR-expressing, TNBC-
derived cell lines and two HER2-amplified breast cancer-derived cell lines. Supplementary Table S1 outlines the 
molecular characteristics for each of these cell lines, which were previously reported14. Results of cell viability 
assays showed that CAT-SKL or SMKI alone had either a relatively modest effect or no effect, but a significant 
loss of viability due to three-day combined treatment was observed for four of the six TNBC cell lines, including 
MDA-MB-468, SUM-149, SUM-159, and HCC-70 (Fig. 1). Each of these four cell lines showed some level of 
lack of response to erlotinib treatment that was overcome by co-treatment with CAT-SKL. Treatment with CAT-
SKL or erlotinib, alone or in combination, appeared to have no effect on TNBC cell lines MDA-MB-231 and 
HCC1937.
For each of the HER2-amplified breast cancer cell lines tested— SUM-225 and SUM-190— loss of viability 
was observed for single agent treatment with CAT-SKL, and treatment with HER2-specific SMKI CP724,714 
appeared to induce a maximum effect. The response to combination of CP724,714 and CAT-SKL was not signif-
icantly different compared to CP724,714 alone (Fig. 1). The results suggest that targeted inhibition of the HER2 
oncogene by CP724,714 treatment superseded any potential benefit of CAT-SKL co-treatment.
CAT-SKL and erlotinib individually act on different sub-populations of TNBC cells. Next, we 
investigated if CAT-SKL or erlotinib were targeting distinct sub-populations of cells in TNBC cell line cultures. 
Using a mammosphere formation assay that calls for culturing breast cancer cells under non-attachment con-
ditions in CSC-selective serum-free media, we tested if CAT-SKL influenced the formation of mammospheres 
demonstrating the presence of CSCs15, in cultures of MDA-MB-468 and HCC70 cell lines. For both of these 
cell lines, the addition of CAT-SKL to the mammosphere-forming media decreased both the numbers of mam-
mospheres and the size of surviving mammospheres (Fig. 2A,B and E,F). Similar results were observed when we 
used the same conditions on MDA-MB-231 cells (Fig. 2C,G), which appeared non-responsive to erlotinib and/
or CAT-SKL according to viability assay data (Fig. 1). We also tested the effect of CAT-SKL on CSC self-renewal 
potential using already formed mammospheres, here allowing MDA-MB-468 mammospheres to establish and 
grow for five days before starting a seven-day course of CAT-SKL treatment. Results showed a marked reduction 
in mammosphere size (Fig. 2H).
To test the independent effects of erlotinib and CAT-SKL on CSCs and non-CSC bulk cancer cells we iso-
lated each cell sub-population by fluorescence-activated cell sorting (FACS). CSCs were isolated based on triple 
marker-positive status (CD44+ /CD133+ /EpCAM+ ); and isolated non-CSC bulk cancer cells expressed none 
of these cell surface protein markers; i.e., triple marker-negative (CD44/CD133/EpCAM). We confirmed that 
the triple marker-positive cells thrived in CSC-selective, mammosphere-forming culture conditions and that the 
triple marker-negative cells could not be maintained under those conditions (Fig. 3A). We also confirmed that 
CAT-SKL inhibited growth of the triple marker-positive cells maintained in mammosphere-forming conditions 
(Fig. 3B,C). It was observed in parallel that treatment of triple marker-positive CSCs with CAT-SKL for seven 
days caused an increase in G2/M checkpoint and subG0 cell cycle arrested fractions and induced cell death (Sup
plementary Tables S2 and S3).
Finally, we immediately re-plated FACS-isolated sub-populations under short-term attached culture condi-
tions to measure the effects of independent CAT-SKL or erlotinib treatment using the cell viability assay as in 
Fig. 1. The results showed that CAT-SKL had no effect on triple marker-negative cells, but specifically decreased 
viability of the triple marker-positive CSCs (Fig. 3D,E). Treatment with erlotinib had the reverse impact; erlotinib 
specifically and significantly inhibited viability of the bulk triple marker-negative cells and had no effect on CSCs 
(Fig. 3F,G).
Discovery of a CAT-SKL-regulated, CSC-supporting factor by analysis of whole genome 
expression and validation. For insights as to what gene(s) CAT-SKL may be regulating to impact the 
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CSC phenotype we used a microarray approach to measure whole-genome expression in CAT-SKL-treated and 
control-treated MDA-MB-468 cell cultures. We conducted a time-course experiment collecting mRNA data every 
6 hours over the course of 30 hours of treatment and starting at the pre-treatment, zero time-point. The objective 
of our data analysis approach described in Methods was to identify gene transcripts showing time-dependent 
expression level changes (greater than two-fold, log2) only in the CAT-SKL-treated condition. These criteria 
identified 21 candidate genes (Supplementary Figure S4). Based on compelling data in the literature to support 
that the CSC phenotype is modulated at the level of gene transcription, reviewed in ref. 16, we assessed our result-
ing gene set to identify transcriptional regulators and selected the methyl-CpG binding domain 2 (MBD2) gene 
for further investigation. The data for MBD2 displayed a significant and sustained decreased expression in the 
CAT-SKL-treated condition and showed no change in the control cultures (Fig. 4A).
Hypothesizing that downregulation of MBD2 gene expression was a key factor in CAT-SKL inhibition of CSC 
viability and self-renewal, we used mammosphere assay culture conditions to test the effect of transient siRNA 
knockdown of MBD2 expression in FACS-isolated, triple marker-positive MDA-MB-468 CSCs. We used two 
commercially available pre-validated MBD2-targeted siRNA constructs independently, and for each the result 
was a significant reduction in the numbers of viable mammospheres and reduced mammosphere size (Fig. 4B,C 
and Supplementary Figure S5). In confirming MBD2 knockdown by immunoblot analysis we observed that the 
siRNA treatment was preferentially downregulating a short form variant (Fig. 4D and Supplementary Figure S5). 
Its immunoblot estimated molecular weight corresponds with an alternative mRNA splicing variant known to the 
NCBI as variant 2 (of 2), also known as MBD2c in the literature17. These data suggested that the CSC-inhibiting 
effect of the MBD2-targeted siRNA treatment was linked to downregulation of the short isoform MBD2c. To 
further test this and the role of MBD2c specifically in promoting CSCs, we proceeded to stably overexpress the 
Figure 1. Effect of CAT-SKL and SMKI treatments, alone and in combination, on viability of various breast 
cancer cell lines. Cell viability was measured following 72 hours of treatment. SUM-225 and SUM-190 are 
HER2-amplified cell lines that were treated with SMKI CP,724,714 that specifically inhibits HER2. The other 
cell lines, which express EGFR and represent TNBC, were treated with the EGFR-targeted SMKI erlotinib. Each 
experiment was run in triplicate and panels are representative of 3 independent experiments, *p < 0.05.
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MBD2c variant in MDA-MB-468 cells (Fig. 4E,F), and observed that this caused a significant increase in the 
numbers of viable mammospheres and an increase in mammosphere size (Fig. 4G,H).
Characterization of MBD2 isoform levels in FACS-sorted triple marker-negative non-CSCs and in triple 
marker-positive CSCs, and whether or not CAT-SKL preferentially impacted either one of the isoforms became 
the next important issues to address. Using the MDA-MB-468 cell line, we measured the relative mRNA levels 
of MBD2a and MBD2c in FACS-isolated triple marker-negative bulk cells and in triple marker-positive CSCs. 
Here we learned that MBD2a transcript levels were always greater than MBD2c (Fig. 5A), and that MBD2a 
was expressed at nearly the same levels in both cell niches (Fig. 5B). In contrast, a comparison of MBD2c tran-
script levels showed that MBD2c was nearly four times higher in triple marker-positive CSCs relative to triple 
marker-negative cells (Fig. 5C). Thus, while MBD2a levels were at a similar level in both cancer cell subtypes, 
MBD2c was significantly higher in the triple marker-positive CSC fraction.
We moved forward to measure the effect of CAT-SKL on MBD2 isoform expression in FACS-isolated triple 
marker-positive CSCs. According to both RT-PCR and immunoblot methods CAT-SKL treatment significantly 
reduced MBD2c levels, but had no detectable impact on high-level MBD2a expression (Fig. 5D–F).
Figure 2. Effect of CAT-SKL on mammosphere formation and self-renewal capacity in CSC-enriched 
cultures. (A–C) A mammosphere assay was used to measure the impact of CAT-SKL treatment on the 
numbers of mammospheres formed per 1,000 cells passaged, 3 different TNBC cell lines were investigated: 
MDA-MB-468, HCC70 and MDA-MB-231. (D) Confirmation that heat inactivated CAT-SKL does not have 
the same effect as active CAT-SKL. (E–G) Mammosphere images are representative of the effect of CAT-
SKL to reduce mammosphere size using MDA-MB-468, HCC70 and MDA-MB-231 TNBC cell lines (40x 
magnification). (H) Effect of CAT-SKL on CSC self-renewal potential using already formed mammospheres, 
here allowing MDA-MB-468 mammospheres to establish and grow for five days before starting a seven-day 
course of CAT-SKL treatment. Results showed a marked reduction in mammosphere size (40x magnification). 
Each experiment was run in triplicate and panels are representative of at least 2 independent experiments, 
*p < 0.05; ns, not significant.
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Regulation of triple marker-positive CSCs and the MBD2c isoform is recapitulated with appli-
cation of antioxidant (−)-epicatechin. The final sets of data presented are from experiments designed 
to learn if treatment with other antioxidants could replicate the effects of CAT-SKL (1 uM) to inhibit growth of 
self-renewing CSCs and downregulate MBD2c in TNBC cell cultures. We tested a range of subnanomolar to 
micromolar concentrations of resveratrol and N-acetyl-L-cysteine (NAC) on MDA-MB-468 cells, and none rep-
licated the effects of CAT-SKL (data not shown). Using (−)-epicatechin (100 uM) we observed that alone it had 
no significant effect on viability of MDA-MB-468 cell cultures in attached growth conditions. The combination of 
(−)-epicatechin plus erlotinib, however, did significantly decrease cell viability (Fig. 6A). Alone, (−)-epicatechin 
also potently decreased mammosphere-formation and growth (Fig. 6B–E). Finally, (−)-epicatechin treatment of 
MDA-MB-468 cell cultures caused a reduction of MBD2c mRNA and MBD2c protein levels, while MBD2a levels 
were unchanged (Fig. 6F,G).
Figure 3. Testing the independent effects of erlotinib and CAT-SKL on CSCs and non-CSC bulk cancer 
cells isolated from MDA-MB-468 cell cultures. We isolated each cell sub-population from MDA-MB-468 
cells by fluorescence-activated cell sorting (FACS). CSCs were segregated based on triple marker-positive status 
(CD44 + /CD133 + /EpCAM + ); and non-CSC bulk cells were isolated based on absence of all of these markers 
(i.e., triple marker-negative). (A) Triple marker-positive cells thrived in CSC-selective, mammosphere-forming 
culture conditions and triple marker-negative cells could not be maintained under these conditions (14 days 
of culture, 10x magnification). (B) For triple marker-positive cells maintained in mammosphere-forming 
conditions, CAT-SKL inhibited mammosphere formation and (C) mammosphere growth (40x magnification). 
In the bottom panels, FACS-isolated sub-populations were immediately re-plated under short-term attached 
culture conditions to measure the effects of independent CAT-SKL or erlotinib 3 day treatments using the cell 
viability assay: (D) Effect of CAT-SKL treatment on triple marker-negative cells; (E) Effect of CAT-SKL on triple 
marker-positive CSCs; (F) Effect of erlotinib treatment on triple marker-negative cells; (G) Effect of erlotinib 
on triple marker-positive CSCs. Each experiment was run in triplicate and panels are representative of at least 2 
independent experiments, *p < 0.05; ns, not significant.
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Discussion
In the coming years, new advances in precision cancer medicine will depend on combining drugs to target the 
heterogeneity of tumor cells to improve patient survival outcomes. Moreover, to overcome the persistence of de 
novo and developed drug resistance, more effective therapeutic strategies must target the most aggressive subset 
of cancer cells that give rise to metastatic recurrence16. These clinical challenges underscore the value of the pres-
ent study. We found that treatment with the antioxidant CAT-SKL selectively impacted CSCs and treatment with 
the SMKI erlotinib targeting EGFR selectively impacted non-CSCs. Thus, combining the antioxidant CAT-SKL 
with the SMKI erlotinib targets both CSCs and bulk cancer cells in cultures of EGFR-expressing TNBC-derived 
cell lines.
The results from testing the SMKI plus CAT-SKL antioxidant combination on a set of molecularly diverse 
breast cancer-derived cell lines suggest that the treatment strategy could be of substantive benefit to patients if 
developed as a molecularly targeted therapy for TNBC that overexpresses EGFR. However, the data also indicate 
that CAT-SKL will not provide added anti-cancer benefit when another oncogene, such as HER2, is the molecular 
co-target. This interpretation of our HER2-amplified cell line data is in line with understanding that the HER2 
oncogene has a role in promoting CSCs and that inhibition of HER2 signaling reduces CSCs in tumors18.
We report evidence that the mechanism for CAT-SKL inhibition of CSCs in TNBC cultures may depend 
on antioxidant-induced downregulation of epigenetic reader MBD2, more specifically isoform MBD2c. A 
recent report by Lu et al. delineates opposing functions for MBD2a and MBD2c in human pluripotent stem 
cells (hPSCs)17. Their data support the mechanistic model where in hPSCs MBD2a binds methyl-CpG promoter 
sequence and recruits the Nucleosome Remodeling and Deacetylase co-repressor complex (NuRD) to silence 
Figure 4. Identification and validation of the potential importance for CAT-SKL regulation of MBD2.  
(A) a time-course microarray approach to measure whole-genome expression identified the methyl-CpG 
binding domain protein 2 (MBD2) gene as being regulated by CAT-SKL in comparing CAT-SKL-treated and 
control-treated MDA-MB-468 cell cultures. The time-course experiment collected mRNA data every 6 hours 
over the course of 30 hours and starting at the zero time-point. (B–C) Mammosphere assay culture conditions 
were used to test the effect of transient siRNA knockdown of MBD2 expression in FACS-isolated, triple 
marker-positive MDA-MB-468 CSCs (panel C, 40x magnification). (D) Confirmation of MBD2 knockdown 
by immunoblot analysis using beta-actin as a control showed that the siRNA treatment was preferentially 
downregulating a short form variant. The molecular weight corresponds with alternative mRNA splicing 
variant known to the NCBI as variant 2 (of 2), also known as MBD2c in the literature. For a measure of MBD2a 
in whole cell lysates the immunoblot exposure time was 15 seconds (s), for MBD2c the exposure time for the 
same blot was 30 minutes (m). (E) Verification of stable MBD2c overexpression by semiquantitative RT-PCR 
using RPLPO as the houskeeping control gene (Ct, mean cycle threashold). (F) Verification of stable MBD2c 
overexpression by immunoblot analysis of nuclear lysates using P62 as a control. All immunoblot bands are 
cropped, full-length blot images are provided in Supplementary Figure S7. (G,H) Mammosphere assay culture 
conditions were used to test the effect of stable MBD2c overexpression in MDA-MB-468 cells relative to green 
fluorescent protein (GFP)-expressing MDA-MB-468 control cells (panel H, 40x magnification). The siRNA 
knockdown and stable overexpression experiments were done twice, independently and in triplicate, *p < 0.05; 
ns, not significant.
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transcription of genes required for pluripotency, thus MBD2a promotes hPSC differentiation. Furthermore, in 
hPSCs it appears that MBD2c binds the same densely methylated promoter sequences17; and because MBD2c 
lacks the C-terminal coiled-coil domain required to recruit the NuRD complex as depicted in Fig. 6H 19, upregu-
lated MBD2c competes with MBD2a for methyl-CpG DNA binding to activate genes and promote pluripotency 
in hPSCs17. As such, our findings that implicate MBD2c in the promotion of TNBC CSCs are novel, yet provide 
another example of how signaling pathways in CSCs and hPSCs may be similar20.
On the other hand, our data also indicate that there is likely to be a distinction for MBD2c function in CSCs 
in comparison to hPSCs. In studying TNBC CSCs we observe that levels of MBD2a are far higher than MBD2c 
levels, approximately four- to five-hundred times higher according to semiquantitative RT-PCR analysis and our 
immunoblot data are in-line with that (noting that to achieve similar band intensity, using the same blot and 
an antibody that detects both17, the exposure time for MBD2a was less than thirty seconds while the MBD2c 
exposure time was thirty minutes). This suggests that a co-occupying, competitive methyl-CpG DNA binding 
model may not extend to TNBC CSCs. Moreover, compared to MBD2a, MBD2c lacks both the NuRD-recruiting 
Figure 5. Measure of MBD2 isoform levels in triple marker-negative non-CSCs and in triple marker-
positive CSCs and the effect of CAT-SKL on isoform levels. Using the MDA-MB-468 cell line, the relative 
mRNA levels of MBD2a and MBD2c were measured in FACS-isolated triple marker-negative bulk cells and in 
triple marker-positive CSCs. Semiquantitative RT-PCR analysis showed that (A) MBD2a transcript levels were 
by far greater than MBD2c in both cell sub-types, and (B) MBD2a was expressed at nearly the same levels in 
both cell niches. (C) In contrast, a comparison of MBD2c transcript levels showed that MBD2c was nearly four 
times higher in triple marker-positive CSCs relative to triple marker-negative cells. (D) The effect of CAT-SKL 
on MBD2a and (E) MBD2c isoform expression in MDA-MB-468 FACS-isolated triple marker-positive CSCs 
according to semi-quantitative RT-PCR, and by (F) immunoblot methods using nuclear protein isolate. For 
MBD2a the immunoblot exposure time was 15 seconds (s), for MBD2c the exposure time for the same blot was 
30 minutes (m). Each bar graphed experiment was run in triplicate and panels are representative of at least 2 
independent experiments, *p < 0.05; ns, not significant. The immunoblot experiment was independently done 
twice.
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coiled-coil domain and the intrinsically disordered region (IDR). Presence of the IDR increases the binding 
affinity of MBD2 for methylated DNA21. Altogether, these findings raise the idea that MBD2c may regulate a tran-
scriptional program independent of MBD2a in TNBC CSCs. This is a line of investigation we intend to pursue. 
Further analysis will also be required to understand how treatment with CAT-SKL causes a reduction in MBD2c 
transcript and protein, possibly by mechanisms that undermine transcript stability or that impinge on the process 
of alternative MBD2 mRNA splicing.
Our work also tested multiple antioxidants and identified a second that recapitulated the effects of CAT-SKL 
on TNBC CSCs. More work needs to be done to understand why, but only select antioxidants appear to be effec-
tive. CAT-SKL at 1 uM delivers catalase enzyme function that targets hydrogen peroxide and (−)-epicatechin 
used at 100 uM is a flavonoid that is known to chemically react with hydrogen peroxide22, and both downregu-
lated MBD2c in CSCs and inhibited self-renewing CSC growth. They each also were shown to reduce intracellu-
lar and extracellular hydrogen peroxide levels (Supplementary Figure S6). This report underscores the need for 
future research to learn more about the role of ROS signaling in tumor initiating cancer cells. Moreover, further 
research is needed to understand how CAT-SKL, (−)-epicatechin and reduction of hydrogen peroxide function— 
regarding both the site of action and impact on signaling pathways— to affect MBD2c and CSCs. Nonetheless, as 
both (−)-epicatechin and CAT-SKL have been used therapeutically in mice11,23,24, pre-clinical research into the 
potential utility of combining an antioxidant with an anti-EGFR drug in treating breast cancer may be relatively 
straight forward.
Figure 6. Regulation of triple marker-positive CSCs and the MBD2c isoform by (−)-epicatechin.  
(A) (−)-epicatechin (100 uM) alone had no significant effect on viability of MDA-MB-468 cell cultures in 
attached growth conditions. The combination of (−)-epicatechin plus erlotinib, however, did significantly 
decrease cell viability. (B–E) Alone, (−)-epicatechin also potently decreased mammosphere-formation and 
growth (panel E, 40x magnification). (F,G) Using FACS-isolated triple marker-positive MDA-MB-468 cells 
demonstrated that (−)-epicatechin treatment caused a reduction of MBD2c mRNA and protein levels, and that 
MBD2a levels were unchanged. For a measure of MBD2a in nuclear protein isolates the immunoblot exposure 
time was 15 seconds (s), for MBD2c the exposure time for the same blot was 30 minutes (m). (H) Representation 
of the MBD2 gene and coding structures and exons (E) for alternative mRNA splicing variants MBD2a and 
MBD2c (NCBI variants 1 and 2, of 2); arrows represent the location of primers used in semi-quantitative 
RT-PCR analysis. Each bar graphed and mammosphere experiment was run in triplicate and panels are 
representative of at least 2 independent experiments, *p < 0.05; ns, not significant. The immunoblot experiment 
was independently done twice.
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We and others have shown that increased intracellular ROS levels in breast cancer cells have a signaling role 
that promotes breast carcinogenesis and cancer progression9,25. Also, increased levels of ROS in cancer cells are 
tightly regulated— kept in check by upregulation of enzymes such as superoxide dismutase (SOD)— in order for 
cancer cells to survive26. It remains to be seen how and under what molecular circumstances oncogenic ROS can 
be effectively targeted to treat breast cancer. Research has been ongoing from the perspective that inhibition of 
SOD, which converts the more reactive superoxide radical −O2  to less reactive hydrogen peroxide, can cause the 
accumulation of superoxide radicals causing cell damage leading to cancer cell death26. Our investigation into a 
reengineered catalase biologic offers new molecular insight for breast cancer. In summary, the results indicate that 
a decrease in hydrogen peroxide by CAT-SKL treatment in combination with an EGFR inhibitor holds promise of 
a novel, therapeutic modality to treat TNBC, a breast cancer subtype with the worst prognosis and high need for 
treatment options.
Methods
Cell lines and culture conditions and treatment agents. The previously established human triple 
negative breast cancer and HER2-positive breast cancer cell lines were recently acquired for this study from the 
American Type Culture Collection (ATCC, Manassas, VA) or from the Biobanking and Correlative Sciences Core 
(BCSC) at the Karmanos Cancer Institute (KCI, Detroit, MI). The BCSC provides a record of authenticity for each 
cell line lot based on short tandem repeat (STR) analysis. HCC-70 cells were maintained in 5% FBS RPMI-1640 
media containing amphotercin B and gentamycin at 37 °C, 5% CO2. All other cells were maintained in 5% FBS 
DMEM media containing amphotercin B and gentamycin at 37 °C, 5% CO2. Erlotinib, CP724,714 and -(−)epi-
catechin were from Sigma-Aldrich (St. Louis, MO). We previously showed that CP724,714, which was originally 
developed by Pfizer Inc. (Groton, CT), specifically inhibits HER2 activity9. CAT-SKL is a reengineered form of the 
antioxidant enzyme catalase, formulated and prepared as described previously11,12,27–29.
Measurement of Hydrogen Peroxide. The activity of CAT-SKL to reduce hydrogen peroxide in 
breast cancer cell cultures was confirmed using two distinct assays. The first known as the Amplex Red Assay 
kit (Thermo Fischer Scientific, Waltham, MA) measured extra-cellular hydrogen peroxide. Performed follow-
ing the manufacturers instructions, 2000 cells were seeded in 100 uL of 5% FBS DMEM media onto wells of 
a 96-well plate and cultured for 18 hours. Then, media was replaced with the same media or the same media 
with 1 uM CAT-SKL. Hydrogen peroxide levels were measured after 24 hours of treatment using a Synergy 2 
plate reader (Biotek, Shoreline, WA). The second approach measured intracellular hydrogen peroxide levels 
using the MAK164 Intracellular Assay kit (Sigma-Aldrich). Here following the manufacturers protocol, after 
24 hours CATSKL-containing media was washed away by a PBS rinse before the hydrogen peroxide sensor 
solution was applied and measurements using a Synergy 2 plate reader were taken after a 4 hour incubation. 
Supplementary Figure S6 displays the significant impact of CAT-SKL and -(−)epicatechin treatments on hydro-
gen peroxide levels in breast cancer cell cultures.
Cell viability assay (attached cultures). Cell viability was measured using the CellTiter-Glo luminescent 
assay kit (Promega, Madison, WI), following the manufacturers instructions. 3,000 cells were seeded per well in 
100 uL of culture media in 96-well plates. The next day, the media was changed and the compounds were added 
by dilution in the fresh media. Viability was measured after 3 days of treatment using a Synergy 2 plate reader.
Mammosphere formation assay. The presence of and self-renewal capacity of cancer stem cells (CSCs) was 
examined in breast cancer triple negative cell lines by the mammosphere formation assay, as described previously15. 
Briefly, 1,000 single cells were seeded in 1.5 mL of the FBS-free sphere formation media (1:1 DMEM:F-12 media 
plus with B-27 and N-2 supplements, Gibco/Life Technologies) in 6-well Ultra Low Attachment plates (Corning 
Inc., Corning, NY). The treatments were replenished every 3 days. After 7 days of incubation, the mammospheres 
(equal or greater than 50 micrometer diameter) were counted and reported as a fraction of the total number of 
cells seeded. To assess self-renewal capacity mammospheres were allowed to form and grow for 5 days. Then, 
treatments were added and replenished every 3 days after. After 7 days of treatment the mammospheres were 
counted. Images were taken using a Nikon Eclipse TE2000-U microscope.
Isolation of CSC triple-marker positive cells. To test the independent effects of erlotinib and CAT-SKL 
on CSCs and non-CSC bulk cancer cells we isolated each cell sub-population by fluorescence-activated cell sort-
ing (FACS), which was done at the Karmanos Cancer Institute Microscopy, Imaging and Cytometry Resources 
Core (KCI MICR). CSCs were segregated based on triple marker (CD44+ /CD133+ /EpCAM+ ) positive sta-
tus; and isolated non-CSCs expressed none of these markers (i.e., triple marker-negative). We confirmed that 
the triple marker-positive cells thrived in CSC-selective, mammosphere-forming culture conditions and that 
the triple marker-negative cells could not be maintained under those conditions. Isolated triple marker-positive 
CSCs were cultured in the FBS-free mammosphere formation media to maintain the undifferentiated status. 
Fluorochrome-labeled monoclonal antibodies against human CD44, CD133, and EpCAM proteins were obtained 
from EBiosciences (San Diego, CA), Miltenyl Biotec (Cologne, Germany), and BD Biosciences (Franklin Lakes, 
NJ), respectively.
Cell cycle analysis. DAPI-staining and flow cytometric assay was conducted at the KCI MICR Core to assess 
the cell cycle under different experimental conditions. After washing, the cells were fixed with 4 mL of 75% eth-
anol at − 20 °C overnight. The fixed cells were washed and stained with DAPI solution (Sigma, 1 mg/mL stock 
solution) at 4 °C for 3 h, followed by flow cytometric analysis.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7:44125 | DOI: 10.1038/srep44125
Apoptosis assay. Annexin V-PI-staining/flow cytometric assay was conducted to examine the effect of 
CAT-SKL on apoptosis in CSC-like cells. Briefly, after treatment, the cells were harvested, washed with PBS solu-
tion once, and further processed to apoptosis assay by using FITC Annexin V/Dead Cell Apoptosis kit (Thermo 
Fisher Scientific, Waltham, MA), and FACS analysis at the KCI MICR Core.
Semi-Quantitative RT-PCR of mRNA. We conducted semi-quantitative RT-PCR analysis as previously9. 
RNA was extracted from cells using the Qiagen (Valencia, CA) RNeasy kit. RNA was converted into cDNA via 
a reverse transcription reaction using oligo dt primers and the qScript cDNA Synthesis kit (Quanta Biosciences, 
Beverly, MA). 20 uL reactions were run in 96-well plates, using 100ng cDNA and SYBR Green Master Mix 
(Thermo Fischer Scientific). Reactions were run in triplicate using the StepOnePlus Real-Time PCR System 
(Thermo Fischer Scientific). Primer pairs specific to MDB2a or MDB2c were previously reported in ref. 17. Actin 
was used as the reference gene. All primers were from Integrated DNA Technologies Inc. (Coralville, IA). Relative 
quantification was calculated using the delta-delta Ct method30.
Statistical analysis. The cell line data are presented as the mean and standard deviation of a representative 
experiment. Semiquantitative RT-PCR data are presented as the mean of multiple experiments with the stand-
ard error of the mean. Student T-test was performed to test the significance of difference between two groups, a 
p-value equal or less than 0.05 is considered to be statistically significant.
Time-course, whole genome expression profiling by microarray analysis. Whole genome expres-
sion analysis was conducted as we have done previously9,31. Briefly, MDA-MB-468 cell cultures were treated with 
CAT-SKL (1 uM) or vehicle control (media diluent), and RNA was isolated using the RNeasy Kit (Qiagen, San 
Diego, CA) from parallel plated cultures at 0 h and every 6 hours after start of treatment for 30 hours, yielding 6 
time points. Expression levels were determined by microarray analyses using the Illumina human HT-12v4 array 
(Illumina, San Diego, CA). Data were processed for quality control in GenomeStudio (detection p-value < 0.01), 
background subtracted, log2 transformed and quantile normalized. Raw and analyzed data sets are available 
through NCBI Gene Expression Omnibus accession number GSE69799.
We applied a filtering method to the log2, normalized expression data, introduced by us previously31, which 
separates time-course gene expression profiles that can be fit to linear models from chaotic expression profiles. 
We further filtered this result to identify 21 genes showing fold-change ≥ 2 log2 in the course of CAT-SKL treat-
ment, and fold-change ≤ 1.5 log2 in the control time-course.
Transfection of MBD2 and control siRNA in breast cancer cells. A pre-validated human MBD2 
siRNA constructs (catalogue ID numbers s17079 and s17080) and a control non-silencing, scrambled construct 
(catalogue number 4390846) were purchased from Thermo Fisher Scientific (Waltham, MA). MDA-MB-468 cells 
were transfected with these constructs using DharmaFECT reagent also from Thermo Fisher Scientific, following 
the manufacturer protocol.
Stable overexpression of MBD2c in breast cancer cells. Packaged lentiviral particles to overexpress 
GFP and MBD2c were purchased from Cyagen Biosciences (Santa Clara, CA). The human MBD2c (NM015832.4) 
gene was custom synthesized and subcloned into a lentiviral expression vector downstream of a CMV promoter 
region (same as for GFP). The construct was sequenced to ensure that the sequence and orientation were correct. 
Similar to what we have done before8, MDA-MB-468 cells were transduced with lentivirus and selected with 
puromycin. MBD2c expression levels were detected using semi-quantitative RT-PCR and Western blotting.
Immunoblot analysis. Immunoblot analysis to detect the relative levels of MBD2 proteins in whole cell 
lysate or nuclear extracts was performed as we have previously done9. Briefly, 50 ug of total protein from each 
sample were loaded and separated on 10% SDS-PAGE gels, and then transferred to a nylon membrane using 
Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, Hercules, CA). Membranes were probed with primary 
antibodies following suppliers recommendation and secondary peroxidase-conjugated antibodies (anti-mouse 
or rabbit). Primary antibodies included: polyclonal anti-human MBD2 (Bethyl Laboratories, Montgomery, TX) 
that was used previously17, and monoclonal beta-actin and monoclonal nucleoporin P62 (both Sigma-Aldrich) 
for whole cell and nuclear extract controls, respectively.
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